Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vibeke Strand

Showing results (331-340 of 436) with videos related to

Pageof 44
Sort By:
Rheumatology (Oxford, England)|September 1, 2020
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritisLaura C Coates, Joseph F Merola, Philip J Mease, et al.
Clinical and Experimental Rheumatology|May 10, 2016
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trialsGene V Wallenstein, Keith S Kanik, Bethanie Wilkinson, et al.
Arthritis Research & Therapy|July 27, 2020
Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviewsRikke A Andreasen, Lars E Kristensen, Xenofon Baraliakos, et al.
The Journal of Rheumatology|May 5, 2007
Outcome measures in psoriatic arthritisDafna D Gladman, Philip J Mease, Paul Healy, et al.
Clinical and Experimental Rheumatology|December 21, 2019
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan studyVibeke Strand, Désirée van der Heijde, Yoshiya Tanaka, et al.
The Journal of Rheumatology|October 17, 2016
Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working GroupLouise Klokker, Peter Tugwell, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|September 28, 2016
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trialDaniel J Wallace, Vibeke Strand, Joan T Merrill, et al.
Annals of the Rheumatic Diseases|January 19, 2018
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trialRonald F van Vollenhoven, Edward Clark Keystone, Vibeke Strand, et al.
Seminars in Arthritis and Rheumatism|March 31, 2024
Increasing uptake through collaboration in the development of core outcome sets: Lessons learned at OMERACT 2023Beverley Shea, Jordi Pardo Pardo, Shawna Grosskleg, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2019
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III StudyDésirée van der Heijde, Vibeke Strand, Yoshiya Tanaka, et al.
Pageof 44

Showing results (331-340 of 436) with videos related to

Sort By:
Pageof 44
Rheumatology (Oxford, England)|September 1, 2020
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritisLaura C Coates, Joseph F Merola, Philip J Mease, et al.
Clinical and Experimental Rheumatology|May 10, 2016
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trialsGene V Wallenstein, Keith S Kanik, Bethanie Wilkinson, et al.
Arthritis Research & Therapy|July 27, 2020
Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviewsRikke A Andreasen, Lars E Kristensen, Xenofon Baraliakos, et al.
The Journal of Rheumatology|May 5, 2007
Outcome measures in psoriatic arthritisDafna D Gladman, Philip J Mease, Paul Healy, et al.
Clinical and Experimental Rheumatology|December 21, 2019
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan studyVibeke Strand, Désirée van der Heijde, Yoshiya Tanaka, et al.
The Journal of Rheumatology|October 17, 2016
Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working GroupLouise Klokker, Peter Tugwell, Daniel E Furst, et al.
Annals of the Rheumatic Diseases|September 28, 2016
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trialDaniel J Wallace, Vibeke Strand, Joan T Merrill, et al.
Annals of the Rheumatic Diseases|January 19, 2018
Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trialRonald F van Vollenhoven, Edward Clark Keystone, Vibeke Strand, et al.
Seminars in Arthritis and Rheumatism|March 31, 2024
Increasing uptake through collaboration in the development of core outcome sets: Lessons learned at OMERACT 2023Beverley Shea, Jordi Pardo Pardo, Shawna Grosskleg, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|January 23, 2019
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III StudyDésirée van der Heijde, Vibeke Strand, Yoshiya Tanaka, et al.
Pageof 44